Close menu




January 14th, 2022 | 11:44 CET

BioNTech, Defence Therapeutics, PAION - Seizing the momentum

  • Biotechnology
Photo credits: pixabay.com

The Corona pandemic brought biotechnology to the forefront of society's consciousness, especially since the first vaccines were created in German laboratories. However, the biotech spectrum is much broader than pandemic vaccine research. In addition to research in medicine, the sector is playing an increasingly important role in environmental protection, agriculture and the ongoing climate change.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , DEFENCE THERAPEUTICS INC | CA24463V1013 , PAION O.N | DE000A0B65S3

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Sudden rise

    How quickly it can happen in the biotech sector that a company that has been inconspicuous for years can quickly become a new star on the stock market is shown by the example of the Mainz biotechnology company BioNTech. BioNTech was founded in 2008 as BioNTech RNA Pharmaceuticals GmbH based on many years of research work. The focus was on the development and production of technologies and drugs for individualized cancer immunotherapies based on mRNA.

    As of early 2020, BioNTech developed the vaccine BNT162b2, also known as Comirnaty, which, as is well known, is successfully marketed globally in collaboration with the US pharmaceutical company Pfizer. At the same time, the vaccine is the first approved product of the German flagship company, and 20 other potential drugs are said to be in the development pipeline, according to BioNTech.

    The IPO took place shortly before the outbreak of the Corona pandemic in October 2019 on the US technology exchange Nasdaq, with an issue price of USD 15 per share. After that, the stock price soared, fueled by positive studies and final approval. The high was USD 464.00 in August 2021. That was followed by a major correction of more than 60%, which is rather the technical normality for such growth stocks. Nevertheless, the stock market value still stands at USD 53.57 billion.

    From a chart perspective, BioNTech may have completed a bottoming process at USD 200. At first glance, the stock is too expensive as a one-product company. On the other hand, if you listen to science, mRNA technology is likely to have made the breakthrough through the development of an adequate vaccine, which means that more BioNTech products in the field of cancer research should only be a matter of time.

    Platform approach with potential

    Far less well known than BioNTech is the Canadian company Defence Therapeutics. The Mainz-based Company is also miles ahead of the stock market value, which currently stands at just under EUR 130 million. In terms of valuation, however, the gap could narrow in the future due to the Company's proprietary platform. Defence Therapeutics aims to develop the next generation of vaccines and ADC products.

    Market researchers at Emergen Research forecast that the antibody-drug conjugate (ADC) market will reach a total volume of USD 20.01 billion by 2028, growing at nearly 26% per year.

    At the core of the Defence Therapeutics platform is ACCUM technology, which enables precise delivery of vaccine antigens or ADCs in the intact form to target cells, revealing fewer side effects. As a result, improved efficiency and efficacy against many diseases such as cancer and infections can be achieved.

    Important milestone

    The new year 2022 began with a bang and the achievement of an important milestone. The final step in the GLP studies on the lead molecule AccuTOX ™ for combating cancer was initiated at Eurofins Advinus Limited before the start of its phase I study in breast cancer patients. The global market for breast cancer therapeutics is huge and growing extremely fast. According to Fortune Business Insights, it had a market size of USD 17.8 billion in 2018 and is expected to grow to USD 38.5 billion by 2026.

    As such, Eurofins, a leading contract research organization in drug discovery and development, has been contracted to perform all final FDA and Health Canada mandated GLP studies on its lead molecule. Completing this series of GLP studies represents the final step before Defence Therapeutics approaches the FDA and Health Canada to initiate a Phase I study in breast cancer patients in 2022.

    China deal provides breathing room

    The biotechnology company PAION also had an extremely successful start to the first days of the year. Since the beginning of the year, the share price has risen from EUR 1.20 to EUR 1.60. The rapid increase was due to the sale of its patent rights to Remimazolam in China. These are being sold to a subsidiary of Humanwell Healthcare. PAION will receive around EUR 20.5 million for the rights and the associated royalties.

    Jim Philipps, CEO of PAION, is excited about the new growth opportunities: "This significant, non-dilutive financing will allow us to further invest in the expansion of our European sales teams for our three approved products in anesthesia and critical care. It will allow us to invest in our own sales growth toward the goal of becoming a sustainably profitable specialty pharmaceutical company over the next three years."


    Research into vaccines due to the Corona pandemic has brought the importance of biotechnology to the general public's attention. BioNTech has already achieved an ambitious valuation, and with further successes in terms of cancer treatment, Defence Therapeutics still has significant growth potential through its platform technology. The cash that has been freed up could generate new revenue growth for PAION.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on March 1st, 2024 | 17:05 CET

    Cardiol Therapeutics, Bayer, Coinbase - Which share will generate profits in the long term?

    • Biotechnology
    • Pharma
    • crypto

    The world of pharmaceuticals and life sciences is characterized by precisely documented studies in clinical research. If an active ingredient makes it to approval, there is the potential for a blockbuster worth billions. Cardiol Therapeutics has an active ingredient in the second phase of clinical research for the treatment of heart disease in people under 35 years of age. This active ingredient can also restore the quality of life of 26 million people worldwide who suffer from heart failure. Bayer continues to clean up the unresolved issues left behind by the former CEO. Did the weedkiller RoundUp® from the Monsanto deal possibly lead to improper treatment due to a lack of consumer protection information? The five-figure lawsuits still pending against Roundup are dampening the share's profit prospects. The situation is currently quite different in the cryptocurrency market. Bitcoin is outperforming everyone, and the Coinbase share is benefiting from it. Which investment generates profits in the long term?

    Read

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.

    Read

    Commented by André Will-Laudien on February 16th, 2024 | 07:00 CET

    MorphoSys and Cardiol Therapeutics in upward mode, while Bayer and Pfizer are in slow mode

    • Biotechnology
    • Pharma

    The biotech sector has made a very differentiated start to the new year. While the old favorites are barely moving, the second-line stocks MorphoSys and Cardiol Therapeutics are making a real splash. At Bayer, the bad news just won't go away, and despite a successful major takeover, Pfizer has not yet found its forward gear. After a rally of almost 15% in December, the Nasdaq Biotechnology Index (NBI) has taken a pause in the current year. Now, everyone is waiting for the first interest rate cut by central banks. Inflation is already falling, and the negative economic data for the Eurozone is increasing. The ECB would normally be in demand. What should investors urgently keep an eye on?

    Read